Pulmonary embolism
Therapeutic area
Vascular Medicine
Rare disease
No
- Definition
- The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pulmonary embolism
- Therapeutic area
- Vascular Medicine
- pulmonary embolism
- embolism, pulmonary
- pulmonary embolism
- pulmonary embolism (disease)
- pulmonary embolus
- Severity
- Severe
- Cardiology
- Vascular Medicine
- MONDO ID
- MONDO:0005279
- Parent condition
- MONDO:0000473
Related records
Broader conditions (6)
- Arterial disorder
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Human disease
- Vascular disorder
Narrower conditions (1)
- Puerperal pulmonary embolism
Trials (772)
- : Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
- 'Bubble Time' in Pulmonary Embolism
- 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China
- 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
- 3 Screen Electronic Alert
- 3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism
- 68Ga PET/CT Versus 99mTc SPECT/CT for Lung Perfusion and Ventilation Scintigraphy; a Technical and Practical Feasibility Study
- A Clinical Trial to Evaluate the Efficacy and Safety of TwiFlow-System for Acute Pulmonary Embolism
- A Different Approach to Preventing Thrombosis
- A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
- A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
- A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay
- A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
- A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
- A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli
- A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter
- A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
- A Prospective Study for the Treatment of Severe Pulmonary Embolism With Pharmacodynamic Thrombectomy
- A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System
- A Random Selection of Patients From the SENTRY Study Who Have a Bioconverted Sentry IVC Filter in Situ With a Minimum Dwell Time of 24 Months From a Single Center Follow up
Approved drugs (10)
- Alteplase
- Apixaban
- Dabigatran etexilate mesylate
- Edoxaban tosylate
- Enoxaparin sodium
- Fondaparinux sodium
- Heparin sodium
- Rivaroxaban
- Technetium TC 99M pentetate
- Warfarin sodium
Drugs in development (15)
- Acenocoumarol Phase 3
- Diclofenac Phase 2
- Drotrecogin alfa (activated) Phase 2
- Furosemide Phase 3
- Heparin Phase 3
- Idraparinux Phase 3
- Idraparinux sodium Phase 3
- Ioforminol Phase 2
- Macitentan Phase 3
- Nitric oxide Phase 2
- Oxygen Phase 3
- Sildenafil Phase 1
- Tenecteplase Phase 3
- Urokinase Phase 2
- Warfarin Phase 3
Other linked drugs (6)
- Edoxaban
- Fibrinogen, human
- Fondaparinux
- Phenindione
- Semaglutide
- Streptokinase